Intercept +5.6% AH on FDA fast-track designation

|About: Intercept Pharmaceuticals (ICPT)|By:, SA News Editor

The FDA has granted fast-track designation for the use of obethicholic acid (OCA) for treating primary biliary cirrhosis (PBC).

Intercept (ICPT) plans to complete a new drug application for OCA in 1H15. The NDA will include data from Intercept's Phase 3 trial and two randomized Phase 2 trials.